Jen‐Chung Ko - Concepedia

Author

Jen‐Chung Ko

National Taiwan University Hospital ORCID

Also Known As

J C Ko, J. Ko, J.-C. Ko, JC Ko, Jeff C. H. Ko, Jen-Chung Ko, Jen‐Chung Ko, Junghoon Ko, Ko, Jen-Chung

106

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

National Taiwan University Hospital National Chiayi University National Yang Ming Chiao Tung University Yuanpei University Ministry of Health and Welfare

About

Jen‐Chung Ko is an author at National Taiwan University Hospital specializing in medicine, lung cancer, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	28	837
2	Health Sciences	2	2	41
3	Nursing	1	1	37
4	Anesthesia	1	1	41
5	Biochemistry	1	1	27

Jen‐Chung Ko

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Exploring Volatile Organic Compounds in Breath for High-Accuracy Prediction of Lung Cancer Ping‐Hsien Tsou, Zong-Lin Lin, Yu-Chiang Pan, Cancers	2021	115
Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells Jen‐Chung Ko, Jyh‐Cheng Chen, Tai‐Jing Wang, Biochemical Pharmacology Tumor BiologyOncologyMitomycin C-induced CytotoxicityMedicineCell Death	2016	75
Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells Jen‐Chung Ko, Ying-Jhen Su, Szu‐Ting Lin, Biochemical Pharmacology Oncogenic AgentMedicineCell DeathEmodin-mediated CytotoxicityCancer Biology	2009	69
Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma Sheng‐Kai Liang, Min‐Shu Hsieh, Meng‐Rui Lee, Oncotarget	2017	63
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells Jen‐Chung Ko, Shih‐Ci Ciou, Chao‐Min Cheng, Carcinogenesis Chemotherapeutic AgentsOncologyTumor MicroenvironmentMmc TreatmentMedicine	2008	59
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells Chun‐Hao Pan, Ying-Fang Chang, Ming-Shuo Lee, BMC Cancer	2016	57
Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination Ming‐Han Kuo, An-Chun Lee, Shih-Hsin Hsiao, Cancer Research	2020	54
Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2 Jen‐Chung Ko, Ying-Jhen Su, Szu‐Ting Lin, Lung Cancer Cancer ResearchCell RegulationMedicineCell DeathRadiation Oncology	2009	53
Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinase–AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Non–Small Cell Lung Cancer Cells Jen‐Chung Ko, Shih‐Ci Ciou, Jhih-Yuan Jhan, Molecular Cancer Research ApoptosisSignaling PathwaysCell DeathCancer BiologyTumor Biology	2009	47
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations Sheng‐Kai Liang, Jen‐Chung Ko, James Chih‐Hsin Yang, Lung Cancer MedicineLung AdenocarcinomaUncommon Egfr P.l747pPathologyBronchial Neoplasm	2019	44

Page 1